




16TH ANNUAL HEALTHCARE INVESTOR CONFERENCE

.....

10th October 2024



Why it has never been more important to tell the right story

Read invaluable insights from Europe's leading life sciences investors on how to attract investment in Optimum's **European Life Sciences Investor Survey 2024.**



↓ **DOWNLOAD**



“ Investors are proactively looking for new investments and many are expecting to devote more time to them. European companies need to be communicating a strong and compelling investment story. ”

Mary Clark

Chief Executive Officer, Optimum Strategic Communications

New 2024/25
report due soon!

WELCOME TO OPTIMUM'S 16TH ANNUAL HEALTHCARE INVESTOR CONFERENCE

Welcome to our 16th Annual Healthcare Investor Conference! The theme for this year is 'Back to growth' and after three years of depressed markets, 2024 has seen the life sciences sector bounce back with a return to deal making.

Good companies with great science are getting the capital they need to develop the life-changing drugs required to fill the looming patent cliff Pharma is facing in 2025 onwards. With markets estimating that c.\$230 billion of Pharma revenue needing to be replaced by 2030, there has never been a better time for biotechs to sharpen their story, get their name out there and get the deal they deserve.

However, in a competitive market, companies must be ready to capitalise on this rebounding investor appetite and make the most of deal opportunities when they arise. The groundwork must be laid: prospective investors and partners need to be informed about what you are doing, why your technology is so transformational, and why your team are the best and will deliver.

At Optimum, we specialise in helping companies do just that. During the last 12 months, we have advised a record number of clients through fundraisings, transformational deal making and M&A, as well as new product approvals. So far this year, we have advised on 25 M&A and licensing transactions (ten of which, where the value was disclosed, had a combined deal value of c.\$4 billion), as well as 42 fundraisings totalling \$3.5 billion. Many of those clients are here today and we want to celebrate their success and thank them for their trust and confidence in Optimum.

This year, we once again have a truly illustrious group of speakers to engage you in lively discussion and debate. Top investors will share their insights on where they are looking to deploy funds, outline which therapeutic areas are 'hot' right now and where they see those trends heading, and industry experts will advise on the different considerations for securing investment on both sides of the Atlantic.

There will also be plenty of time to network with the array of life science leaders, fund managers and analysts who are attending – and who truly make our conference so special. I'd like to personally thank everyone for taking the time to be here.

As always, we encourage questions and debate during the conference, so please participate in person and join the conversation on social media using today's hashtag [#OptimumConference2024](#). A summary of the sessions will feature on our website and social media channels in the coming weeks.

Our featured charity this year is Muscular Dystrophy UK. I am delighted to welcome Martin Hywood who will tell us about the incredible support the charity offers individuals with muscle wasting or weakening conditions – a subject very close to the Optimum family. Please donate if you can.

I would like to thank our sponsors, Babraham Research Campus, Citi, Cooley, ICG and Nasdaq, for their support.

We have an exceptional team of people at Optimum, all of whom will be at the conference. Our US Partners, Gilmartin are also here today – so please do introduce yourselves.

I hope you enjoy today. Please join us for the evening drinks reception that follows. It will be a great opportunity to connect with peers and colleagues, old and new.

Best wishes,

Mary & The Optimum Team

Mary Clark, CEO, Optimum Strategic Communications



INTERNATIONAL STRATEGIC COMMUNICATIONS USING OUR MULTI-CHANNEL APPROACH

For Life Sciences, Healthcare & Industrial Biotechnology

We are specialists with an in depth understanding of how to communicate complex scientific information to key stakeholders and help you through various growth stages. We have been trusted by hundreds of clients, both public and private, large and small, to help them on their journey.



Strategic, proactive & effective corporate communications and investor relations in Europe and US helping clients communicate a compelling story to important stakeholders



Healthcare, life sciences & industrial biotech specialists who have worked with over 400 companies



Successful track record helping companies raise their profile in the international top tier media



Unrivalled network of contacts in the investment community and media, across Europe and US



Multi-channel communications approach to create powerful impact



In-depth research and analysis, combined with knowledge of the global healthcare industry, enabling us to provide clients with the best-informed and most creative advice to build a compelling investment story



Team of experienced, senior specialist healthcare advisors

MEET THE OPTIMUM TEAM




Mary
Clark



Nick
Bastin



Hollie
Vile



Jonathan
Murphy



Eva
Haas



Zoe
Bolt



Stephen
Adams



Hana
Malik



Richard
Staines



Vici
Rabbetts




Premal
Pajwani



Charlotte
Hepburne-Scott



Eleanor
Cooper



Elena
Bates



Katie
Flint



Josh
Evans



Varen
Outhonesack



Aoife
Minihan



Abbie
Murphy




Ellie
Reston



Monica
Clark



Karsa
Ambikaibakan



Mochi



AGENDA

10:00am-12:00pm Registration

11:00am-12:00pm **How to have a successful IPO on Nasdaq**

Market overview by Nasdaq and Citi

- Isabella Schidrich, Senior Managing Director, Nasdaq Stock Exchange
- Asaf Homossany, Senior Managing Director, Nasdaq Stock Exchange
- Niccolò Cominacini, Director, Citi

How IPO comms works in the US by Gilmartin Group

Getting your story right, building momentum & market visibility

Chair: Nick Bastin, Managing Director, Optimum

- Lynn Lewis, Founder & CEO, Gilmartin Group
- Mary Clark, CEO, Optimum
- Eva Haas, Managing Director, Optimum
- Premal Pajwani, Founder PRP Advisory & Senior Consultant, Optimum

12:00pm-12:50pm **Networking lunch**

Sponsored by Citi & Nasdaq

12:55pm-1:00pm **Welcome from Mary Clark, Chief Executive Officer, Optimum**

1:00pm-2:00pm **How European biotech can navigate everchanging capital markets**

Chair: Catherine Pickering, Co-founder & Chief Executive Officer, iOnctura

- Allan Marchington, Managing Director & Head of Life Sciences, ICG
- Dr Gil Bar-Nahum, Managing Director, Jefferies International
- Francesco De Rubertis, Co-founder & Partner, Medicxi
- Gemma Game, Head of Healthcare, Equity Strategies, Norges Bank Investment Management

2:00pm-2:50pm **Fireside chat: Accelerating innovation**

Chair: Dr Daniel Mahony, Senior Partner, Novo Holdings, Growth Investments

- Nerida Scott, Head, Johnson & Johnson Innovation, EMEA

2:50pm-3:20pm **Tea break & networking**

Sponsored by Babraham Research Campus

3:25pm-4:15pm

Fireside chat: Investing in “healthspan”

Chair: Clive Cookson, Senior Science Writer, Financial Times

- Dr Mehmood Khan, CEO, Hevolution Foundation

4:15pm-5:15pm

Scaling up: How to build European champions

Chair: Simon Amies, Partner, Cooley

- Renée Aguiar-Lucander, CEO, Calliditas Therapeutics
- Geraldine O’Keeffe, Partner, EQT
- Kieran Murphy, Chairman, Gamma Biosciences & SPT Labtech
- Hakan Goker, Managing Director, M Ventures

5:15pm-5:25pm

Featured charity: Muscular Dystrophy UK introduced by Optimum

- Hollie Vile, Managing Director, Optimum
- Martin Hywood, Regional Corporate New Business Officer, Muscular Dystrophy UK

5:25pm

Thank you & conclusions from Optimum

5:30pm-7:30pm

Networking reception drinks

Sponsored by Cooley and ICG

Thank you to our sponsors



How to have a successful IPO on Nasdaq

With Nasdaq now the undisputed global destination of choice for a public market listing, what do companies need to consider from an investor communications stand point when planning for an IPO? With a very different regulatory environment from the UK or European markets, hear our experts discuss what the key opportunities and pitfalls are, and how long term planning is essential for success.




Chair: Nick Bastin, Managing Director, Optimum

Nick Bastin has over 30 years of experience advising companies and individuals from over 35 different markets on a wide range of multi-market, multi-stakeholder communications. Nick specialises in helping clients build powerful narratives around corporate reputation, employer brand and investor and capital market objectives. Nick has strong transaction experience, having clients raise over €30bn through IPOs and advised on M&A transactions with a combined deal value in excess of €150bn.



Niccolò Cominacini, Director, Citi

Niccolò Cominacini currently runs the Depositary Receipt Sales team for UK & Europe. He has extensive client experience both in sales and account management, he previously had direct responsibilities for clients in the Life Sciences sector such as Adaptimmune, Immunocore or Orchard Therapeutics. Niccolò earned his MBA from IESE Business School, Barcelona. He also holds an MSc degree in Economics and Finance from Bocconi University, Milan. Prior to Citi, he worked for Accenture in Spain and the USA.



Isabella Schidrich, Senior Managing Director, Nasdaq Stock Exchange Listings, Europe

Isabella Schidrich, Senior Managing Director, has been responsible for business development of Nasdaq in Europe since 2001. Isabella has worked with hundreds of European companies, supporting a Nasdaq listing and managing the relationship with the Capital Markets community (investment banks, PE / VC firms, IR/PR firms, legal / accounting firms) and Nasdaq-listed companies in Europe. Prior to that, Isabella gained extensive business development experience within the telecommunications industry, heading business units at BT Group and at Deutsche Telekom AG, and within the Services Industry. Isabella holds a Master in Business Administration from Munich University (Germany).



Asaf Homossany, Senior Managing Director, Nasdaq Stock Exchange Listings, Europe

Asaf Homossany is a Senior Managing Director at Nasdaq responsible for the Nasdaq listing business in EMEA. He has over 25 years of experience in global capital markets and during his tenure with Nasdaq has supported over 250 companies from the EMEA region (including Israel, UK, France, the Nordics, Middle East and South Africa, as they listed on Nasdaq.

In his role, Asaf is responsible for Nasdaq's listing strategy in EMEA, including supporting pre-IPO companies, VCs, PE funds and advisers in the region with capital raising in the US or on any of Nasdaq's European exchanges. An expert on IPOs, capital raising and capital markets, Asaf is familiar with the unique challenges that SMEs and growth companies face when navigating this space. He works closely with management teams of private companies as they prepare for their IPOs on Nasdaq and their transition into the public markets but also oversees the on going relationships between such companies and Nasdaq post IPO to help them maximise the benefits of being a listed company in the US.



Lynn Lewis, Founder and Chief Executive Officer, Gilmartin Group

Lynn spent the first half of her career as a Wall Street equity research analyst and investor focused on evaluating innovative companies within the medical device and healthcare sector. She pivoted in 2008 to strategic consulting with emphasis on investor relations, capital markets advisory and support in forecasting financial and operational milestones. Having created and executed investor relations programs and strategies for over 100 companies (public and private) at various stages of development, Lynn has a proven track record of success.

Prior to founding Gilmartin Group, Lynn was a Managing Director at Westwicke Partners offering strategic counsel to public and private entities, with specific emphasis on medical technology, diagnostics, and life sciences. Lynn was previously a Founder and Portfolio Manager at Aphelion Capital, a healthcare fund focused on public and private investments and prior to that, was a Partner at Thomas Weisel Partners (now Stifel Nicholas) and a Sr. Vice President at Adams & Harkness & Hill (now Canaccord Genuity) in equity research.



Mary Clark, Chief Executive Officer, Optimum

Mary Clark has a 25 year successful track record in providing strategic corporate and financial communications to both early and late stage healthcare companies and has worked with over 400 biotech and healthcare clients across Europe and the US. She has developed several high-profile investor focused campaigns and has been instrumental in strategic positioning ahead of fundraising rounds of private financings, IPOs and follow-on public financings.

She founded Optimum in 2017 with the mission to provide the best strategic communications advice and implement effective communications programmes to achieve high impact results. Previously, Mary built and led healthcare businesses at several international PR & IR agencies. She started her career at BTG plc where she was involved in the Company's IPO and the start-up of several new tech and biotech companies.



Eva Haas, Managing Director, Optimum

Eva Haas has 25 years' experience in fund management and company analysis across the global healthcare sector. She lived in New York for seven years covering the US. She was previously at Schroder Investment Management where she was responsible for the analysis and valuation of publicly listed and about-to-be-listed healthcare companies in medical devices and supplies, diagnostics, biotechnology, pharma, life sciences tools, healthcare distribution, pharmacy benefit management, hospitals & health insurance. Eva has a PhD in Biochemistry from Bristol University. She is also a fluent German speaker.



Premal Pajwani, Founder of PRP Advisory and Senior Advisor to Optimum

Premal Pajwani is a Senior Adviser to Optimum and is the founder and principal of PRP Advisory, a specialist independent healthcare consultancy firm. Premal previously worked as the Global Healthcare Specialist for J.P. Morgan Asset Management in London for eight years.

Prior to this, Premal was a Healthcare Portfolio Manager with First State Investments. From 2000 to 2007, Premal was a Pharmaceutical and Healthcare Analyst at J.P. Morgan Securities and Eden Financial. From 1991 to 2000, Premal worked as a Research Analyst covering Pharma at various banks and brokers in New York City. Premal holds an M.B.A. from the University of Cincinnati and a B.Com. from the University of Mumbai, India.

How European biotechs can navigate everchanging capital markets

With the global life sciences market roaring back to life after a flat few years, join our panel of experts from across the market to discover what is hot and what is not as investors look to put their capital to work.




Chair: Catherine Pickering, Co-Founder and Chief Executive Officer, iOnctura

Catherine Pickering holds a PhD in Medicinal Chemistry and an MBA. During her career, she has held various licensing and business development positions in pharma and biotech. Before founding and building iOnctura, she led the global oncology and immunology licensing and business development function at Merck. During her time at Merck, she was also an integral member of the oncology franchise leadership team, a cross functional team responsible for creating the strategy and managing the oncology business.



Allan Marchington, Managing Director and Head of Life Sciences, ICG

Allan Marchington joined ICG in January 2021 and is Managing Director and Head of Life Sciences, responsible for the Life Science Fund strategy and team at ICG. Prior to ICG, Allan was Founder and Managing Partner of Bridge Valley Ventures, a successful life science investor, having been a Partner and Founder of Apposite Capital. Before this, Allan was at Abingworth. Formerly a PhD medicinal chemist at Pfizer, he later founded and was CEO of his own life sciences company before it was successfully acquired by Millennium Pharmaceuticals Inc. in 2000 where he became SVP Technology. On his return to the UK in 2003, Allan joined Abingworth to begin his investment career.




Dr Gil Bar-Nahum, Managing Director, Jefferies International

Dr Gil Bar-Nahum is a Managing Director in the Global Healthcare Investment Banking Group at Jefferies and focuses on the Life Sciences universe in Europe, Israel and Asia.

Dr Bar-Nahum has over 14 years of investment banking experience and was most recently an Executive Director for UBS Investment Bank's Global Healthcare Group since 2002. Prior to that, Dr Bar-Nahum worked as a Biotechnology Research Analyst for UBS where he served as an Associate Director covering companies in the Life Science Tools space. Dr Bar-Nahum has executed and advised on over 90 transactions across the globe in the life sciences space, with particular expertise in biotechnology.

Dr Bar-Nahum received his PhD in Basic Medical Sciences with a focus in Biochemistry from the Sackler Institute at the New York

University School of Medicine. The subject of Dr Bar-Nahum's doctorate work was published twice in the journal Cell. Dr Bar-Nahum also received a MS from New York University's School of Medicine in Cell and Molecular Biology and a BS from the University of Illinois in Microbiology.



Francesco De Rubertis, Co-Founder and Partner, Medixi

Francesco De Rubertis is a Co-Founder and Partner at Medixi. Prior to Medixi, Francesco was a Partner at Index Ventures for 19 years, having joined the firm in 1997 to launch its life sciences practice. Under his leadership, the asset-centric approach to life sciences investing was conceived and implemented. Francesco currently serves on the boards of a number of portfolio companies, including Centessa Pharmaceuticals, Rivus Pharmaceuticals, Levicept, Alys Pharmaceuticals, TOAD Oncology and Kaerus Biosciences.

Francesco's prior investments include CellZome (acquired by GlaxoSmithKline), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Vaxcyte (NASDAQ:PCVX), Molecular Partners (SIX:MOLN), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix), Profibrix (acquired by The Medicines Company) and Versartis (NASDAQ:VSAR).

Francesco received a BA in Genetics and Microbiology from the University of Pavia and a PhD in Molecular Biology from the University of Geneva. He conducted postdoctoral research at the Whitehead Institute at MIT and is a CFA Charterholder.



Gemma Game, Head of Healthcare, Equity Strategies, Norges Bank Investment Management

Gemma Game is a Senior Portfolio Manager responsible for Healthcare at Norges Bank Investment Management. She has over 20 years' experience investing in the global healthcare sector. Gemma joined NBIM in 2014 from AXA Investment Managers, where she was head of the healthcare team. Previously, Gemma was a fund manager at BlackRock responsible for healthcare investments on the Global Equity team. Gemma studied Pharmacology at Cambridge University.

Fireside chat: Accelerating innovation

Join Dr Daniel Mahony of Novo Holdings, Growth Investments, as he talks to Nerida Scott, the Head of Johnson & Johnson Innovation EMEA, about her career and her approach to identifying and accelerating science and technology across consumer health, medical devices and pharmaceuticals.



Chair: Dr Daniel Mahony, Senior Partner, Novo Holdings, Growth Investments

Daniel Mahony joined Novo Holdings in 2024 as a Senior Partner in Growth Investments.

Daniel has 25+ years of global healthcare investment experience covering biotechnology, medical technology and healthcare services. In 2007, he co-founded the healthcare business unit at Polar Capital in London, growing it to over \$4 billion in assets under management. Daniel was formerly a Senior Research Analyst at Morgan Stanley in London, an Analyst at ING Barings Furman Selz in New York, and completed his postdoctoral work at DNAX Research Institute in Palo Alto. He currently chairs the UK BioIndustry Association, is a Non-Executive Director of the Wellcome Sanger Institute in Cambridge, and in 2022 was appointed as the UK Government's Life Sciences Envoy.

Daniel received his PhD in Development Biology from the University of Cambridge and his BA in Biochemistry from the University of Oxford.



Nerida Scott, Head, Johnson & Johnson Innovation, EMEA

Nerida Scott is the Head of Johnson & Johnson Innovation EMEA, based at the Innovation Centre (IC) in London, UK. In this role, Nerida oversees the EMEA IC portfolio of co-investments and collaborations to construct, prioritise and advance the early external innovation portfolio of Johnson & Johnson. She identifies and accelerates science and technology outside the company in areas of strategic value to consumer health, medical devices and pharmaceuticals, exploring new models to support external R&D collaboration and grow early-stage innovation networks.

Nerida has been an integral part of the Johnson & Johnson Innovation team since 2015. She was Vice President New Ventures & Transactions, and she led a senior team to identify, develop and execute early-stage transactions with diverse partners in the life sciences ecosystem, including academia, venture capital, entrepreneurs, NGOs and governmental organisations.

Nerida has a broad background in operational and commercial activities, with over 20 years of diverse business and transaction experience in the pharma and healthcare industries having held positions at Vernalis PLC, RiboTargets and The Boston Consulting Group. Nerida received her BSc from Sydney University, Australia, and her PhD in Biochemistry as the Prince of Wales' scholar, Trinity College, Cambridge University, UK. She is a member of the UK BioIndustry Association Board, and on the Board of several Johnson & Johnson entities.

Fireside chat: Investing in “healthspan”


The Hevolution Foundation is the revolutionary new sovereign wealth fund from the Kingdom of Saudi Arabia which is looking to transform our quality of life by investing at scale in extending our “healthspan” – the period of time we live healthy lives. With significant pools of capital to put to work, Clive Cookson talks to Dr Khan on the vision for the fund and the investments the Foundation is looking to make.



Chair: Clive Cookson, Senior Science Writer, Financial Times

Clive Cookson has worked in science journalism for the whole of his professional life. He left Oxford University with a First-Class Honours degree in Chemistry and, after training on the Luton Evening Post, joined Times Higher Education, first as Science Correspondent in London and then as American Editor in Washington.

Clive returned to London as Technology Correspondent of The Times and then moved to BBC Radio as Science and Medical Correspondent. He went back to print journalism as Technology Editor of the Financial Times. From 1991 - 2023 he was science editor at the Financial Times, leading a writing team covering science and health, pharmaceuticals and biotechnology. He has won numerous science journalism awards, including British Science Writer of the Year 2022.



Dr Mehmood Khan, Chief Executive Officer, Hevolution Foundation

Dr Mehmood Khan was formerly Vice Chairman and Chief Scientific Officer of Global Research and Development at PepsiCo, and President of Global R&D at Takeda Pharmaceuticals.

Before moving into the private sector, Dr Khan was a faculty member in endocrinology at the Mayo Clinic and Medical School, where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. He also led programmes in diabetes, endocrinology, metabolism, and nutrition in Minneapolis.

Dr Khan is a member of the Board of Directors of Reckitt Benckiser and of the Saudi Research, Development, and Innovation Authority (RDIA). He is Executive Chairman of Life Biosciences, a member of the Saudi National Biotechnology Strategy Steering Committee, and Chairman of the Visiting Committee on Advanced Technology of the United States' National Institute of Standards and Technology (NIST).

Scaling up: How to build European champions

While the US is often seen as dominating the life sciences landscape, European champions can succeed and flourish in this competitive environment. Join our highly experienced panel and hear how they have achieved success in building highly innovative businesses.



Chair: Simon Amies, Partner, Cooley

Simon Amies is a Partner in Cooley's Life Sciences practice advising on mergers & acquisitions (public and private), initial public offerings and other capital-raising transactions, and venture and growth capital investments. Simon has extensive experience in advising companies at all stages of their development, as well as counselling investors and investment banks. He has represented a wide range of clients in the life sciences, technology and sustainable technology industries.



Renée Aguiar-Lucander, Chief Executive Officer, Calliditas Therapeutics

Renée Aguiar-Lucander has over 30 years of experience in company management, and strategic and financial development of US and European private and public companies with core sector expertise in healthcare and technology. Renée joined Calliditas in 2017 as CEO and has taken the Company from its initial listing on the Swedish stock exchange in 2018 - in what was one of the largest European IPOs that year - to a successful listing on US NASDAQ in June 2020, raising \$90 million, and subsequently building a commercial biopharma company focused on rare disease. Calliditas was the first company globally to successfully complete a Phase 3 study in the rare autoimmune disease, IgA Nephropathy, and to bring the first ever approved drug for the treatment of this disease to market.

Before joining Calliditas, Renée was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Prior to that, she served as a Partner in the venture capital group, 3i Group plc in London, where she managed the publicly quoted assets and was Co-Head of the Global Healthcare and Technology portfolio. Before this, Renée was a European Group Head and Managing Director at a global investment bank where she spent more than 12 years' in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of analytical software for financial services.



Geraldine O'Keeffe, Partner, EQT

Geraldine O'Keeffe joined EQT in 2008 as a Partner within the EQT Life Sciences team. Her association with LSP began the same year and continued until 2022, culminating in the integration of LSP with EQT, subsequently rebranded as EQT Life Sciences.

Before affiliating with LSP, Geraldine served as a Senior Equity Research Analyst at Fortis Bank in Amsterdam, The Netherlands. Prior to Fortis, she held the position of Head of Infectious Disease at Biotrin, a medical diagnostic company based in Dublin, Ireland, which has since become an integral part of Diasorin.

Geraldine holds a BSc Hons in Microbiology and Biochemistry from University College Cork, an MSc in Biotechnology from University College Galway, and a Graduate Diploma in Business Studies from the Dublin School of Business.



Kieran Murphy, Chairman, Gamma Biosciences & SPT Labtech

Kieran Murphy was most recently President and Chief Executive Officer of the \$19B Healthcare division of General Electric.

Prior to overseeing GE Healthcare, he was President and CEO of GE Healthcare Life Sciences, a global leader in life sciences tools and diagnostics providing a broad range of technologies and services for biopharmaceutical research, development and manufacturing. Under Kieran's leadership, GE Healthcare Life Sciences emerged as a market leader in the bioprocessing industry. Before joining GE, Kieran served as CEO of Whatman plc, a global supplier of filters and membranes for life sciences applications.



Hakan Goker, Managing Director, M Ventures

Hakan Goker, PhD, is Managing Director of M Ventures and heads the Biotechnology Investments covering Healthcare and Life Sciences Tools and Technologies. Hakan joined M Ventures in 2013 and has been investing in the sector for 18 years. Previously, Hakan was a partner at Aescap Venture investing in European opportunities. Hakan started his investment career at Atlas Venture, focusing on global investment opportunities in healthcare and medical technologies across the US, Europe and Asia. He was instrumental in the creation, financing, business and R&D strategies of multiple companies in their formation years including Bicycle, Nimbus Discovery, and f-Star while at Aescap and Atlas. Hakan continues his active investing role and represents M Ventures on multiple portfolio companies. He comes from an academic background receiving his PhD in Oncology from the Institute of Cancer Research, University of London, and continuing his scientific career with post-doctoral work at the Breakthrough Breast Cancer Centre, Royal Marsden Hospital. He gained his BSc Hons from University College London. Hakan is based in Amsterdam at the M Ventures head office.

FEATURED CHARITY

Muscular Dystrophy UK

Muscular Dystrophy UK is the leading charity supporting over 60 rare and life-altering muscle-wasting and weakening conditions.

For more than six decades, they have been tirelessly fostering a compassionate community of individuals affected by these conditions, along with their families, carers, scientists, health professionals, supporters, volunteers, and donors. Together, they have achieved extraordinary breakthroughs that would have seemed unimaginable and impossible just ten years ago.

We are pleased to have Martin Hywood and Connal Kelleher join us at the conference today to highlight the great work of the team behind Muscular Dystrophy UK.



Martin Hywood, Regional Corporate New Business Officer, MDUK

Martin Hywood was diagnosed with Limb-Girdle Muscular Dystrophy 25 years ago. Martin describes his journey as an emotional and physical rollercoaster of ups and downs and changes.

Martin attributes the difficulties he has faced as his motivation to help himself and others through his fundraising role for Muscular Dystrophy UK in Partnerships and Ambassador Engagement.

www.muscular dystrophy.org























To read more about Muscular Dystrophy UK or to support the amazing work they do, please visit:

<https://www.muscular dystrophy.org/>

Financings, Deals & Data

Financings

 <p>Oversubscribed €45m Series B Financing</p>	 <p>Extension of Series A Financing to €98m</p>	 <p>Awarded \$595K Grant by The Michael J. Fox Foundation</p>	 <p>\$100m Seed Financing</p>
 <p>\$100m Series C Financing</p>	 <p>€30m Series A Financing</p>	 <p>€16.5m Seed Financing</p>	 <p>\$61m Series A Financing</p>
 <p>€16m Seed Financing</p>	 <p>£40.5m Series A Financing</p>	 <p>€10m Financing</p>	 <p>€20m Seed Financing</p>
 <p>€20m Series A Financing</p>	 <p>\$115m Royalty Financing Agreement</p>	 <p>€80m Series B Financing</p>	 <p>\$75m Private Placement Financing</p>
 <p>£35m Series A Financing</p>	 <p>Novo Holdings Leads \$105m Financing</p>	 <p>\$40m Investment in D3 Bio</p>	 <p>€54m Upsized Financing</p>

mission
therapeutics

£25.2m
Financing

MyricxBio

Novo Holdings
Co-leads \$114m
Series A Financing

NEOPHORE
DYNAMIC MEDICINE EVOLUTION

Oversubscribed
\$39.5m Series B
Financing

NOVO
holdings
Investing to benefit people and the planet

Participates in Series B
Funding of Revagenix

novo nordisk
fonden
Benefiting people and society

\$22m Investment in
Microbiome Health
Initiative

Oxford
NANOPORE
Technologies

£50m Investment
From Novo
Holdings

OUTRUNTX

\$10m Seed
Financing

PHEON
THERAPEUTICS

\$120m Series B
Financing

Resolution **Therapeutics**

£63.5m Series B
Financing

SynOx
Technologies

\$75m Series B
Financing

VESPERBIO

Awarded \$873K
Grant by The Michael
J. Fox Foundation

vicebio

\$100m Series B
Financing

BioIndustrials

21st
BIO

€86m Investment
From Novo Holdings

AMSilk

€54m Series C
Financing Extension

AGNEXT
Quality Food For Billions

Novo Holdings
Investment

CIRCTEC

Novo Holdings
Participates in
€150m Fundraise

Deep Branch
BIOENGINEERING

€8m Series A
Financing

NOVO
holdings
Investing to benefit people and the planet

Awards Grant of up
to \$21.1m to CIMMYT
for CropSustain
Research Initiative

















novo nordisk
fonden
Benefiting people and society

€84.7m Funding to
Establish the World's
First Center for
Carbon Capture

REDUCED

€6m Investment
From Novo Holdings

Deals

 <p>Agreement with Multitude Therapeutics</p>	 <p>Partnership with 21st.BIO to Accelerate Upscaling of Silk Protein Production</p>	 <p>\$1.05bn Acquisition of Novo Holdings Portfolio Company by AstraZeneca</p>	 <p>Partnership with AbbVie</p>
 <p>Acquisition of Laboratorios SL and Synergie Ingénierie Médicale</p>	 <p>Acquisition by Asahi Kasei Corporation for \$1.1bn</p>	 <p>Global License and Development Agreement with Tolmar</p>	 <p>Collaboration with McQuade Center</p>
 <p>\$520m Acquisition of Novo Holdings Portfolio Company by Dechra Pharmaceuticals</p>	 <p>MinervaX and Wacker Biotech Announce Manufacturing Collaboration for GBS Vaccine</p>	 <p>DKK700m Collaboration with NVIDIA for Premises to House AI Supercomputer</p>	 <p>\$1.25bn Acquisition of Portfolio Company, Yellow Jersey Therapeutics, by Johnson & Johnson</p>
 <p>\$13.1bn Acquisition of Sofinnova Partners' Portfolio Company by Johnson & Johnson</p>	 <p>Strategic Partnership with General Inception</p>	 <p>\$216m Collaboration with Spark Therapeutics</p>	 <p>\$740m Licensing Agreement with SOTIO</p>

Awards / News

 <p>Recognised PR Advisors and Credited on 27 Deals in Mergermarket IH24 Rankings</p>	 <p>Founder Awarded British Knighthood for Dedication to Healthcare Innovation and Delivery</p>	 <p>Chief Scientific Officer Receives Rosalind Franklin Society Special Award in Science</p>	 <p>Continued Dedication in Supporting Gender Diversity in Danish Life Sciences</p>
--	--	---	--

Data



Positive Data from RESMAIN Study for Treatment of CTCL



Positive Phase 2 Data from Atrial Fibrillation Clinical Trial



Positive Data Published in Science



Approval of STIMULAN in Brazil



Full FDA Approval of TARPEYO® for Treatment of IgA Nephropathy



Positive Topline Results of Phase 2 Head and Neck Cancer Trial with NOX Inhibitor, Setanaxib



FDA Orphan Drug Designation for Treatment of Multiple Myeloma



Encouraging Preliminary Data from Phase 2 Trial for Lung, Head and Neck Cancer



FDA Orphan Drug Designation for Autotaxin Cancer Therapy



Encouraging Preliminary Data from ATLAS-IT-05 Study



Positive Data from Phase 1b/2a Trial of Treatment for Advanced Liver Cancer



First Launch of BRIUMVI® in Europe for Treatment of Relapsing Multiple Sclerosis



Successful Phase 2 Clinical Data on Fertility Pill, OXO-001, for IVF



Positive Data Confirms POLB 001's Potential in Cancer Immunotherapy-Induced CRS



Positive Results from Phase 1c Clinical Study for Treatment of Obesity



MATCH Phase 2 Study with Autologous Non-engineered Macrophages in Patients with Liver Cirrhosis



Positive Data on METTLI tRNA Methyltransferase Programme



Data from Successful Phase 1 Study of VES001 for Fronto-Temporal Dementia



US FDA Approval of Ohtuvayre™ (ensifentrine)



Launch of Hybrid Closed Loop System for Automated Insulin Delivery in Diabetes

AWARDS 2024

Optimum clients have already won many high profile life science awards in 2024, and the year isn't over yet!



STORM
THERAPEUTICS

Jerry McMahon
Small Molecules



ALCHEMAB
THERAPEUTICS

Jane Osbourn
Biopharmaceuticals



VESPERBIO

Anders Nykjær
Small Molecules



Roman Thomas
DISCO
PHARMACEUTICALS



Jeroen Bakker
NOVO
holdings

AstronauTx

Primary R&D
Company of the
Year

NOVO
holdings

Best Performing
Investor of the
Year

Sofinnova
partners

Best Performing
Investor of the
Year



calliditas
THERAPEUTICS

Executive
of the Year

Commercial Stage
Renée Aguiar-Lucander

calliditas
THERAPEUTICS

Best New
Drug

Tarpeyo (budesonide)
for primary IgA
nephropathy

IONCTURA

Executive
of the Year

Clinical Stage
Catherine Pickering

IONCTURA

Best Oncology
R&D Advance

PI3Kδ inhibitor,
roginolisib

SPLICEBIO

Quris-AI Best
Partnership
Alliance Award

with Spark
Therapeutics



SPEAKERS & SPONSORS



Scan for the e-agenda

INTERNATIONAL STRATEGIC COMMUNICATIONS USING OUR MULTI-CHANNEL APPROACH

For Life Sciences, Healthcare & Industrial Biotechnology

- ✓ Access to investors
- ✓ Sellside analyst relations
- ✓ Media relations
- ✓ Profile raising
- ✓ Corporate communications
- ✓ Conference support
- ✓ Crisis communications
- ✓ Content development
- ✓ Private financing
- ✓ IPOs
- ✓ M&A
- ✓ Perception studies
- ✓ Messaging
- ✓ Narrative development
- ✓ Digital & social media
- ✓ Presentation & media coaching



Optimum's newsroom featuring Optimum TV, podcasts, insights and more from the leaders of life sciences

Amsterdam

London

New York

San Francisco

Stockholm

Zurich





Babraham
Research
Campus

start-up to scale-up



Babraham Research Campus supports the scientific discoveries of tomorrow by nurturing and supporting people, companies and ideas at every stage of the development cycle, making it one of the best places in the world to start, scale and grow a bioscience company.

Impactful science and entrepreneurship activities are developed here which make a tangible difference not only to those on Campus but also beyond.

www.babraham.com



Citi Depository Receipt Services

What is an ADR?

American Depositary Receipts (ADRs) are US\$ denominated equity instruments issued in the US markets through a depository bank. ADRs are used by companies to raise capital in the U.S., with or without a listing in the company's home market.

Why choose an ADR?

ADRs allow companies to broaden their shareholder base and build visibility internationally. ADRs can facilitate merger and acquisition activity through use as an acquisition currency. ADR issuers also benefit from a dedicated account manager who manages company AGMs, employee plans, corporate actions, regulatory and tax matters and provides bespoke reporting on a monthly basis. ADR issuers receive tailored and complimentary investor relations support from a team of former corporate Investor Relations Officers.

Who buys ADR's?

Many different types of investors buy ADRs, from the world's largest institutions to specialist biotech investors and high-net-worth individuals. The market value of ADRs held by institutional investors has increased from \$948bn in 1H2023 to \$1.03 trillion as of 1H 2024.

Companies that have used ADRs for raising capital through Citi as their depository bank:



Disclaimer: The market, service, or other information is provided in this communication solely for your information and "AS IS" and "AS AVAILABLE", without any representation or warranty as to accuracy, adequacy, completeness, timeliness or fitness for particular purpose. The user bears full responsibility for all use of such information. Citi may provide updates as further information becomes publicly available but will not be responsible for doing so. The terms, conditions and descriptions that appear are subject to change; provided, however, Citi has no responsibility for updating or correcting any information provided in this communication. No member of the Citi organization shall have any liability to any person receiving this communication for the quality, accuracy, timeliness or availability of any information contained in this communication or for any person's use of or reliance on any of the information, including any loss to such person. This communication is not intended to constitute legal, regulatory, tax, investment, accounting, financial or other advice by any member of the Citi organization. This communication should not be used or relied upon by any person for the purpose of making any legal, regulatory, tax, investment, accounting, financial or other decision or to provide advice on such matters to any other person. Recipients of this communication should obtain guidance and/or advice, based on their own particular circumstances, from their own legal, tax or other appropriate advisor. Not all products and services that may be described in this communication are available in all geographic areas or to all persons. Your eligibility for particular products and services is subject to final determination by Citigroup and/or its affiliates. The entitled recipient of this communication may make the provided information available to its employees or employees of its affiliates for internal use only but may not reproduce, modify, disclose, or distribute such information to any third parties (including any customers, prospective customers or vendors) or commercially exploit it without Citi's express written consent. Unauthorized use of the provided information or misuse of any information is strictly prohibited. Amongst Citi's affiliates: (i) Citibank, N.A., London Branch is authorized and regulated by Office of the Comptroller of the Currency (USA), authorized by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority and has its UK establishment office at Citigroup Centre, Canada Square, London E14 5LB, (ii) Citibank UK Limited is authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority and has its registered office at Citigroup Centre, Canada Square, Canary Wharf, London E14 5LB, and (iii) Citibank Europe plc UK Branch is authorized by the Central Bank of Ireland and by the Prudential Regulation Authority and subject to regulation by the Central Bank of Ireland, and limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority and has its UK establishment office at Citigroup Centre, Canada Square, London E14 5LB. Outside the UK: (i) Citibank Europe plc ("CEP") is licensed by the European Central Bank and regulated by the Central Bank of Ireland and the European Central Bank under the Single Supervisory Mechanism and has its registered office at 1 North Wall Quay, Dublin 1, and (ii) Citibank Europe plc branches located in the EEA are subject to regulation by the respective host country regulator and the Central Bank of Ireland. This communication is directed at persons: (i) who have been or can be classified by Citi as eligible counterparties or professional clients in line with applicable rules, (ii) Persons in the United Kingdom, who have professional experience in matters relating to investments falling within Article 19(1) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and (iii) other persons to whom it may otherwise lawfully be communicated. No other person should act on the contents or access the products or transactions discussed in this communication. In particular, this communication is not intended for retail clients and Citi will not make such products or transactions available to retail clients. The information contained herein may relate to matters that are: (i) not regulated by the UK Regulator, and/or (ii) not regulated by any applicable financial services regulatory body, and not subject to protections under any relevant law including protection under any applicable financial services compensation scheme. Securities Services © 2024 Citigroup Inc. (organized under the laws of USA with limited liability) and/or its affiliates. All rights reserved. CITI, CITI and Arc Design, CITIBANK and CITIGROUP are trademarks and service marks of Citigroup Inc. and/or its affiliates and are used and registered throughout the world. CBS38533 03/24

Breakthroughs Happen With Cooley

Your legal partner in advancing
life sciences through unrivaled
experience and industry relationships



Cooley

Building Value **Together**

Investor Relations • IPO • Business Strategy • ESG

We Are Your Strategic Partner

Gilmartin Group offers a comprehensive suite of advisory and support services to our clients with the ultimate goal of helping to create durable value for management, corporate boards and shareholders in the healthcare space.

Investor Relations

Capital Markets Advisory

**Strategy & Business
Development Consulting**

**Private Company
Financing Support**

KOL / Analyst Education

IPO Advisory

Messaging & Presentations

Perception Audits

Sector-focused healthcare expertise

- **Biotech**
- **Life Science Tools & Diagnostics**
- **Medtech**
- **Digital Health**
- **Healthcare Services**

✉ **Contact Us**

Info@GilmartinIR.com

**San Francisco
New York
San Diego**

Consulting services provided by Gilmartin Group LLC. Securities products and services offered by Gilmartin Financial LLC, member FINRA/SIPC. Client testimonials may not be representative of the experience of other clients. Testimonials are not guarantees of future performance or success. No clients were paid to provide testimonials. **For Institutional Use only. Not for Retail Investors**

ICG partners with you to build solutions to transform patients' lives



ABOUT US

We are a team of dedicated life science investors with operational and technical backgrounds.

With 30 years of experience and a deep understanding of the industry, we partner with you and provide scale-up capital to transform your business and patients' lives.

WHY CHOOSE US :

- 30 years experience
- Former CEOs who are company builders
- Direct experience with >150 drug development programs
- Track record of investing from blue chip investment firms
- Deep pharma relationships and network

OUR STRATEGY



Therapeutics only



Disease area agnostic



Growth stage opportunities



Scale-up capital (~\$20-100M ticket)



UK, EU and US focus

For more information on the strategy, please contact:

Dr Allan Marchington: Allan.Marchington@icgam.com or ICGLifeSciencesClientRelations@icgam.com



www.icgam.com



www.linkedin.com/company/icg-plc/



www.instagram.com/icgplc/



Nasdaq is proud home to **980+ Healthcare companies** with a combined market capitalisation of **\$2.4T**.

Since 2019, we have welcomed **over 400 Healthcare companies***.



About Nasdaq: Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence.




To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X [@Nasdaq](#), or at www.nasdaq.com.

*Data Source: FactSet, BBC, Nasdaq Listings Qualifications.

THE OPTIMUM NEWSROOM

Have you checked out Optimum's Newsroom?

The Newsroom encapsulates our multi-channel approach, showcasing Optimum TV, podcasts, insights and more from the leaders of life sciences at www.optimumcomms.com/newsroom



OPTIMUM'S NEWSLETTER

Every week, Optimum publishes a short and sweet round-up of client and industry news.

[Subscribe](#) today on LinkedIn or head to the Newsroom!

Are you listening to Optimum Perspectives?

Optimum Perspectives Podcast features regular episodes highlighting the latest innovation and developments in life sciences with industry leaders of the healthcare sector industry.



Listen now on all major streaming platforms



Catch up with all episodes on our website and follow the show to listen as they land!

www.optimumcomms.com/podcast



Dr. Ruth McKernan CBE
Chief Executive Officer
AstronauTx



Søren Møller
Managing Partner
Novo Holdings Seed
Investments



Simon Kerry
Chief Executive Officer
Curve Therapeutics



Dr. Annalisa Jenkins
Non-Executive Director



Jeremy Skillington
Chief Executive Officer
Poolbeg Pharma



Gil Bar-Nahum
Managing Director
Jefferies International



Renée Aguiar-Lucander
Chief Executive Officer
Calliditas Therapeutics



Giusy Di Conza
Head of Research
iOnctura



Chris Martin
Senior VP of Commercial
Verona Pharma



Miquel Vila-Perelló
Chief Executive Officer
SpliceBio



Are you watching Optimum TV?

Bringing you bitesize content from life science leaders -
Talking trends, innovation, capital markets and more...

Available on all major streaming platforms



www.optimumcomms.com

Featuring guests...



Geraldine O'Keefe
EQT



Allan Marchington
ICG



Eliane Schutte
Xeltis



Francesco De Rubertis
Medixi



Michael Bauer
Novo Holdings



Krishna Polu
Commit Biologics



Dr. Agnès Arbat
Oxolife



Amir Hefni
Resolution Therapeutics



Jerry McMahon
STORM Therapeutics



Eva Haas
Optimum



Dr. Daniel Mahony
Novo Holdings



Jason Loveridge
4SC AG



Kieran Murphy
Gamma Biosciences




Stefano Gullà
Kling Biotherapeutics



Nick Bastin
Optimum



David Reynolds
LoQus23



Please contact us to see how we can help your strategic communications
mary@optimumcomms.com

